Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Non Operating Income: 2010-2025

Historic Non Operating Income for Lifecore Biomedical (LFCR) over the last 11 years, with May 2025 value amounting to $171,000.

  • Lifecore Biomedical's Non Operating Income rose 115.52% to $171,000 in Q2 2025 from the same period last year, while for May 2025 it was -$3,000, marking a year-over-year increase of 99.90%. This contributed to the annual value of -$3,000 for FY2025, which is 99.90% up from last year.
  • Latest data reveals that Lifecore Biomedical reported Non Operating Income of $171,000 as of Q2 2025, which was down 48.65% from $333,000 recorded in Q1 2025.
  • Lifecore Biomedical's 5-year Non Operating Income high stood at $333,000 for Q1 2025, and its period low was -$1.1 million during Q2 2024.
  • In the last 3 years, Lifecore Biomedical's Non Operating Income had a median value of -$253,500 in 2024 and averaged -$378,100.
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 340.82% in 2022, then tumbled by 882.69% in 2024.
  • Lifecore Biomedical's Non Operating Income (Quarterly) stood at $330,000 in 2021, then plummeted by 171.82% to -$237,000 in 2022, then crashed by 308.02% to -$967,000 in 2023, then surged by 68.56% to -$304,000 in 2024, then skyrocketed by 115.52% to $171,000 in 2025.
  • Its Non Operating Income stands at $171,000 for Q2 2025, versus $333,000 for Q1 2025 and -$304,000 for Q4 2024.